Alnylam Pharmaceuticals Inc
(NASDAQ:ALNY)
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
top performing ALNY trades
45.00%
30.60%
Recent Trades
Largest Trades
Top Performing
Largest Traders
Most Active Traders
Recent Trades
View the most recent Alnylam Pharmaceuticals trades made by congress members.
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Sale | Feb 15, 2024 | Jan 29, 2024 | House |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Purchase | Feb 15, 2024 | Jan 11, 2024 | House |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Sale | Jan 07, 2024 | Dec 11, 2023 | House |
Daniel GoldmanHouse (D-NY) | $15K - $50K | stock | Purchase | Apr 17, 2023 | Mar 06, 2023 | House |
Daniel GoldmanHouse (D-NY) | $15K - $50K | stock | Sale | Feb 24, 2023 | Jan 31, 2023 | House |
Josh GottheimerHouse (D-NJ) | $1K - $15K | stock | Purchase | Oct 16, 2022 | Sep 28, 2022 | House |